D-dimer is a fibrin degradation product (or FDP), a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis. D-dimer concentration may be determined by a blood test to help diagnose thrombosis in patients with suspected thrombotic disorders. D-dimer test was preferred as an initial test to diagnose thrombosis and rule out DVT in order to reduce the number of patients seeking alternative diagnostic therapy. Non-invasiveness and lack of radiologist intervention are the prominent drivers of quantification of D-dimer levels in deep vein thrombosis detection. It is mostly used to exclude thromboembolic disease and to diagnose blood disorder disseminated intravascular coagulation.
The global D-dimer testing market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021).
The global D-dimer testing market segmentation is based on testing methods (Clinical Chemistry Analyzers, Coagulation Analyzers, Laboratory Testing, Point-of-care Testing), and its applications (Deep Vein Thrombosis (DVT), Disseminated Intravascular Coagulation (DIC), and Pulmonary Embolism (PE).
The global D-dimer testing market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global D-dimer testing market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global D-dimer testing market and included in this report are Abbott Laboratories, Alere, Inc., Beckman Coulter, Inc., Bio/Data Corporation, Becton, Dickinson and Company, Corgenix, F. Hoffman-La Roche Ltd., Helena Biosciences, Siemens Healthcare, Sysmex Corporation, Trinity Biotech, and Thermo Fisher Scientific.